Skip to main content

Table 3 Cox multivariate analysis of recurrence/mortality in patients with tamoxifen monotherapy

From: Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy

  Total ER+ and/or PR+ ER- and PR- ER-/PR-/HER2-
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Recurrence
PostM vs. PreM 1.048 (0.671-1.665) 0.8404 1.154 (0.728-1.879) 0.5482 1.464 (0.561-4.045) 0.4367 1.523 (0.542-4.585) 0.4255
T (>2cm vs. ≤2cm) 1.921 (1.232-3.097) 0.0035* 1.637 (1.016-2.726) 0.0426 4.859 (1.334-31.224) 0.0137* 4.370 (1.165-28.412) 0.0268
LN (+ vs. -) 3.004 (1.953-4.736) <0.0001* 3.466 (2.118-5.898) <0.0001* 1.851 (0.664-5.160) 0.2342 2.438 (0.822-7.620) 0.1075
Grade (II+III vs. I) 1.810 (1.165-2.887) 0.0079* 1.902 (1.184-3.147) 0.0074* 1.296 (0.414-4.933) 0.6696 1.447 (0.454-5.593) 0.5464
ER (+ vs. -) 1.128 (0.634-2.092) 0.6890       
PR (+ vs. -) 0.770 (0.501-1.183) 0.2328       
HER2 (+ vs. -) 1.162 (0.437-2.577) 0.7395 2.002 (0.591-5.117) 0.2347 0.518 (0.080-1.954) 0.3613   
Bcl-2 (+ vs. -) 0.929 (0.604-1.449) 0.7430 0.892 (0.561-1.450) 0.6377 1.745 (0.576-4.804) 0.3078 1.958 (0.621-5.682) 0.2387
Mortality         
PostM vs. PreM 1.084 (0.659-1.822) 0.7532 1.482 (0.863-2.646) 0.1568 0.991 (0.335-2.923) 0.9871 0.869 (0.257-2.898) 0.8166
T (>2cm vs. ≤2cm) 2.498 (1.468-4.506) 0.0005* 2.114 (1.198-3.951) 0.0090* 8.196 (1.545-152.292) 0.0093* 10.872 (1.682-234.909) 0.0081*
LN (+ vs. -) 2.861 (1.768-4.778) <0.0001* 2.997 (1.733-5.430) <0.0001* 1.826 (0.565-6.013) 0.3097 3.070 (0.845-12.889) 0.0888
Grade (II+III vs. I) 1.849 (1.118-3.168) 0.0161* 2.184 (1.258-3.969) 0.0051* 1.079 (0.312-4.332) 0.9076 1.299 (0.367-5.344) 0.6924
ER (+ vs. -) 1.354 (0.714-2.696) 0.3614       
PR (+ vs. -) 0.564 (0.342-0.920) 0.0219*       
HER2 (+ vs. -) 1.188 (0.440-2.697) 0.7099 1.968 (0.577-5.095) 0.2486 0.536 (0.074-2.341) 0.4345   
Bcl-2 (+ vs. -) 0.801 (0.496-1.307) 0.3695 0.688 (0.415-1.161) 0.1591 2.550 (0.797-7.752) 0.1106 3.443 (0.999-11.894) 0.0502
  1. Factors considered other than Bcl-2 were menopausal status, tumor size, nodal status, grade, ER, PR and HER2 status
  2. ER estrogen receptor, PR progesterone receptor; HER2 human epidermal growth factor receptor 2, HR hazard ratio, PostM and PreM postmenopause and premenopause at the time of diagnosis, T tumor size, LN lymph node, + positive, − negative
  3. *Significant, P <0.05.